<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="28680">1-beta-D-Arabinofuranosylcytosine</z:chebi>-5'-stearylphosphate (fosteabine) was administered orally to patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>); <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation, <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> derived from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, in an early phase II study in a multi-institutional study </plain></SENT>
<SENT sid="1" pm="."><plain>Among 62 evaluable patients, 2 patients achieved a complete remission, 6 a good response and 8 partial response by daily oral administration of 100-200 mg of fosteabine </plain></SENT>
<SENT sid="2" pm="."><plain>The overall response rate was 25.8% </plain></SENT>
<SENT sid="3" pm="."><plain>The response rates were almost the same among the four subtypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Responses were reached 2-23 weeks (median, 8 weeks) after the start of therapy and continued for 3-50 weeks (median, 10 weeks) </plain></SENT>
<SENT sid="5" pm="."><plain>Major side effects were <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> and gastrointestinal toxicities </plain></SENT>
<SENT sid="6" pm="."><plain>In spite of the disadvantages, such as unpredictable absorption, this newly developed orally administrable <z:chebi fb="0" ids="28680">cytarabine</z:chebi> analogue will be a useful drug in the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>